{"id":"cm310","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CM310 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing the suppressive signal that tumors use to evade the immune system. By blocking the PD-L1/PD-1 axis, the drug restores T-cell activation and proliferation, enabling the body's immune system to recognize and attack cancer cells more effectively.","oneSentence":"CM310 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:29.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT07388758","phase":"PHASE2","title":"Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":37},{"nctId":"NCT07240376","phase":"NA","title":"Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-11-25","conditions":"Non-Allergic Rhinitis With Eosinophilia Syndrome","enrollment":90},{"nctId":"NCT06495229","phase":"PHASE3","title":"Study of CM310 in Adolescent Subjects With Atopic Dermatis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2024-08-02","conditions":"Atopic Dermatitis","enrollment":180},{"nctId":"NCT06277765","phase":"PHASE3","title":"Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2024-03-21","conditions":"Atopic Dermatitis","enrollment":180},{"nctId":"NCT06300203","phase":"PHASE2","title":"Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-03-18","conditions":"Seasonal Allergic Rhinitis","enrollment":120},{"nctId":"NCT05908721","phase":"PHASE2","title":"Study of CM310 in Patients With Allergic Rhinitis","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2023-08-23","conditions":"Allergic Rhinitis","enrollment":100},{"nctId":"NCT04893707","phase":"PHASE2","title":"The Study of CM310 in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2021-06-07","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":127},{"nctId":"NCT05908032","phase":"PHASE3","title":"Study of CM310 in Subjects With Allergic Rhinitis","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2023-08-10","conditions":"Allergic Rhinitis","enrollment":108},{"nctId":"NCT05579925","phase":"PHASE2","title":"A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-10-07","conditions":"Atopic Dermatitis","enrollment":24},{"nctId":"NCT05131464","phase":"PHASE2","title":"The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2021-11-30","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":46},{"nctId":"NCT05436275","phase":"PHASE3","title":"A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-08-09","conditions":"Chronic Rhinosinusitis With Nasal Polyposis","enrollment":180},{"nctId":"NCT05265923","phase":"PHASE3","title":"A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-04-22","conditions":"Atopic Dermatitis","enrollment":500},{"nctId":"NCT05702450","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2023-03-22","conditions":"Healthy","enrollment":240},{"nctId":"NCT05715320","phase":"PHASE2","title":"Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2023-03-10","conditions":"Atopic Dermatitis","enrollment":160},{"nctId":"NCT06162507","phase":"PHASE1, PHASE2","title":"Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2023-12-22","conditions":"Atopic Dermatitis","enrollment":24},{"nctId":"NCT06547333","phase":"PHASE2, PHASE3","title":"A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-09-13","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":884},{"nctId":"NCT05186909","phase":"PHASE2","title":"A Study of CM310 in Subjects With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-01-12","conditions":"Asthma","enrollment":52},{"nctId":"NCT05761028","phase":"PHASE2, PHASE3","title":"A Study of CM310 in Subjects With Moderate to Severe Asthma","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-04-28","conditions":"Moderate to Severe Asthma","enrollment":600},{"nctId":"NCT06171074","phase":"PHASE2","title":"Study of CM310 in Subjects With Seasonal Allergic Rhinitis","status":"UNKNOWN","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2024-03-30","conditions":"Seasonal Allergic Rhinitis","enrollment":100},{"nctId":"NCT06171048","phase":"PHASE1","title":"Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects","status":"UNKNOWN","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2024-04-30","conditions":"Healthy","enrollment":236},{"nctId":"NCT06161090","phase":"PHASE1","title":"Study of CM310 in Healthy Subjects","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2019-09-03","conditions":"Healthy","enrollment":33},{"nctId":"NCT06116565","phase":"PHASE2","title":"A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2024-03-30","conditions":"Atopic Dermatitis","enrollment":300},{"nctId":"NCT05470647","phase":"PHASE2","title":"A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2022-08-17","conditions":"Allergic Rhinitis","enrollment":93},{"nctId":"NCT05728684","phase":"NA","title":"Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2023-02-28","conditions":"IgG4 Related Disease","enrollment":20},{"nctId":"NCT05452343","phase":"PHASE2","title":"A Study of CM310 in Subjects With Chronic Pruritus","status":"UNKNOWN","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-08-30","conditions":"Chronic Pruritus of Unknown Origin","enrollment":50},{"nctId":"NCT04805398","phase":"PHASE2","title":"Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2021-04-06","conditions":"Chronic Rhinosinusitis (Diagnosis), Nasal Polyps","enrollment":56},{"nctId":"NCT05428410","phase":"","title":"Study on Biomarkers to Predict the Efficacy of IL-4R Monoclonal Antibody for Chronic Rhino-sinusitis With Polyps","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2022-06-17","conditions":"Chronic Rhino-sinusitis, IL-4R, Monoclonal Antibody","enrollment":56},{"nctId":"NCT04805411","phase":"PHASE2","title":"Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2021-02-24","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":120},{"nctId":"NCT04893941","phase":"PHASE1, PHASE2","title":"Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2020-07-21","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IL-4Rα monoclonal antibody"],"phase":"phase_3","status":"active","brandName":"CM310","genericName":"CM310","companyName":"Keymed Biosciences Co.Ltd","companyId":"keymed-biosciences-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CM310 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}